ESC 365 - GLP1 receptor agonists, SGLT2 inhibitors, or both for cardio-renal protection?

ESC Professional Premium Access

GLP1 receptor agonists, SGLT2 inhibitors, or both for cardio-renal protection?

Session: How to protect the kidney in patients with diabetes and heart disease

Topic: Renal Failure and Cardiovascular Disease

Speaker: Assistant Professor A. Van Craenenbroeck (Leuven, BE)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Assistant Professor Amaryllis Van Craenenbroeck

KU Leuven, Leuven (Belgium)

2 presentations

0 follower

3 more presentations in this session

Prevalence and shared mechanisms of cardiovascular-kidney-metabolic syndrome

Speaker: Professor N. Sattar (Glasgow, GB)

Evidence for cardio-renal protection through weight reduction

Speaker: Professor S. Verma (Toronto, CA)

How to protect the kidney in patients with diabetes and heart disease - discussion

Access the full session

How to protect the kidney in patients with diabetes and heart disease

Speakers: Assistant Professor A. Van Craenenbroeck, Professor N. Sattar, Professor S. Verma

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources